QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
09 Novembro 2023 - 6:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of three new kits for use on its QIAcuity systems and a
major new software update designed to expand the portfolio of
applications for use of digital PCR technology in areas like cell
and gene therapies, DNA and RNA quantification, as well as food and
pharmaceuticals safety:
-
The QIAcuity Mycoplasma Quant Kit offers researchers an
accurate and precise way to detect mycoplasma contaminants in all
steps of research and manufacturing of cell and gene therapies. The
kit offers a unique and sensitive workflow that has been validated
by a third party and complies with the mycoplasma testing
frameworks provided by the US, the EU and the Japanese
Pharmacopeia, thus reducing validation effort in-house.
-
The QIAcuity OneStep Advanced EG Kit allows researchers the
highly sensitive quantification of RNA or RNA alongside DNA in one
reaction. The kit uses intercalating dye technology that makes
procedures easier to design and more cost-efficient than those used
in fluorescent-probe-based PCR. In contrast to other chemistry, the
patent-pending HotStart RT enzyme is only active at higher
temperatures, preventing uncontrolled reaction activity while
plates are set up in the lab or waiting for cycling in the QIAcuity
instrument. This allows reaction set-up at room temperature and
leads to more reliable results in multi-plate workflows. QIAGEN’s
OneStep and other innovative chemistry ensures a fast and easy
workflow, with little hands-on time.
-
QIAcuity mericon Food Testing Kits are the only ready-to-use
digital PCR food tests on the market. They enable researchers to
fight product adulteration through target-specific authentication
of food and animal-feed ingredients. The launch sees QIAGEN
extending its large food-safety testing portfolio from traditional
quantitative PCR, providing increased precision and sensitivity, as
well as ensuring dependable data analysis and interpretation.
“The launch of our new QIAcuity kits and the
software update emphasize QIAGEN’s dedication to advancing digital
PCR analysis in crucial sectors like pharma, biopharma research,
and food and drug safety,” said Nitin Sood, Senior Vice President
and Head of the Life Sciences Business Area at QIAGEN. “By
incorporating these innovations into our QIAcuity platform, we are
reinforcing our commitment to providing precise, fast, scalable and
easy-to-use digital PCR solutions for a wide range of
applications.”
Additionally, QIAGEN plans to launch in November
the QIAcuity Software 2.5 update. It is designed to help
researchers determine two key features of digital PCR analyses.
Using the functionality of a temperature gradient, the software
will allow them to determine the precise temperature at which their
experiment should run, saving the need to put the sample through an
external thermocycler during the development of tests to target
specific genetic building blocks.
As sample material is often diluted before being
analyzed by digital PCR, the new software will also calculate the
prevalence of the targeted material in a sample and any dilution
required. After the test, QIAcuity Software 2.5 adjusts for
dilution and converts the results into user-defined units,
automating and documenting a demanding task crucial for
pharmaceutical companies’ reports and audit trails.
QIAGEN’s digital PCR platform QIAcuity uses
nanoplates to disperse a sample over thousands of tiny partitions
and then read the reaction in each one simultaneously to quantify
even the faintest signals from DNA and RNA. The instruments
integrate partitioning, thermocycling, and imaging into one
workflow, cutting processing times to only two hours from six.
The highly versatile QIAcuity systems are
available in one, four, and eight-plate versions, with the
one-plate version processing up to 384 samples in an eight-hour
shift and the eight-plate version up to 1,248 in the same time
period.
Learn more about QIAGEN’s QIAcuity range of
digital PCR kits and devices at
https://www.qiagen.com/us/product-categories/discovery-and-translational-research/pcr-qpcr-dpcr/dpcr-assays-kits-and-instruments.
About
QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024